Aro Biotherapeutics was spun out of Janssen Pharmaceuticals, a Johnson&Johnson company. The focus is in developing a unique protein platform designed to enable optimized delivery of multiple therapeutic payloads to a variety of cell types. Payloads include nucleic acids, gene therapies, cytotoxics, nanoparticles, and other effective therapies across a range of diseases.

Responsible for developing and executing against Celator's Corporate Development Strategy and all aspects if the Commercial Strategy for the lead asset, VYXEOS, the development pipeline, and the CombiPlex technology platform. The strategy ultimately led to the successful exit, in which Celator was acquired for over $1.5 Billion, a significant premium. Oversaw all Business Development activities, and was instrumental in all investor relations activities/financing activities, including confidentially marketed offerings totaling more than $60 Million.Celator, a late stage biopharmaceutical company focused on fundamentally changing the approach to developing oncology drug combinations through our proprietary technology, known as CombiPlex. As Chief Business Officer, my responsibilities included all aspects of Business Development, including identifying commercial partners for ex-US markets for our lead asset, VYXEOS (CPX-351), being studied in high risk Acute Myeloid Leukemia patients. We are established R&D collaborations to apply our CombiPlex technology to novel combinations of molecularly targeted and epigenetic modulators in a variety of major oncology indications. In addition to Business Development, my responsibilities included the development of all commercial planning and ultimate launch of VYXEOS. As a member of the Celator Executive Leadership Team, I was intimately involved with the development of our Corporate Strategy and Communications.

Leading a national team of over 20 Oncology reimbursement specialists, with responsibility for supporting the Genentech Oncology Portfolio (Avastin, Herceptin, Rituxan, Tarceva, Zelboraf, Erivedge, and Xeloda).Our focus is on providing patient access and reimbursement support for patients and health care providers so that patients who are prescribed our innovative cancer therapies can receive them.

Brand and Life Cycle leadership responsibility for Rituxan hematology

Developed commericialzation strategies for development compounds from pre-clin through Ph II Proof of Concept studies. Developed therapeutic areas strategies for biologic therapies in Oncology and Infectious Diseases